Skip to Content
Merck
CN

30020

D-Cycloserine

Synonym(s):

R-4-Amino-3-isoxazolidinone, (R)-4-Amino-3-isoxazolidone, 4-Amino-3-isoxazolidinone

Sign In to View Organizational & Contract Pricing

Select a Size

About This Item

Empirical Formula (Hill Notation):
C3H6N2O2
CAS Number:
68-41-7
Molecular Weight:
102.09
Beilstein:
80798
EC Number:
200-688-4
MDL number:
MFCD00005353
UNSPSC Code:
51102829
PubChem Substance ID:
57648401
NACRES:
NA.85

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

biological source

synthetic

Quality Level

100

form

powder

potency

≥900 μg per mg

color

white to off-white

mp

147 °C (dec.) (lit.)

antibiotic activity spectrum

Gram-negative bacteria
Gram-positive bacteria
mycobacteria

Mode of action

cell wall synthesis | interferes

storage temp.

−20°C

SMILES string

N[C@@H]1CONC1=O

InChI

1S/C3H6N2O2/c4-2-1-7-5-3(2)6/h2H,1,4H2,(H,5,6)/t2-/m1/s1

InChI key

DYDCUQKUCUHJBH-UWTATZPHSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

Chemical structure: amino acid derivatives

Application

D-Cycloserine acts as inhibitor of various enzymes.

Biochem/physiol Actions

Mode of Action: Inhibits cell wall biosynthesis (D-Ala peptide bond formation). Also prevents conversion of D-Ala to L-Ala. Bacteriostatic.
Partial agonist at the glycine modulatory site of NMDA glutamatergic receptors; antibiotic against Gram-negative bacteria.
Mode of Resistance: D-Ala transport interference.
Mode of Action: Inhibits cell wall biosynthesis (D-Ala peptide bond formation). Also prevents conversion of D-Ala to L-Ala. Bacteriostatic. Mode of Resistance: D-Ala transport interference.

Packaging

1g, 5g, 25g

Other Notes

Keep container tightly closed in a dry and well-ventilated place. Store under inert gas. Air sensitive. Keep in a dry place.

Storage Class Code

11 - Combustible Solids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Regulatory Information

涉药品监管产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000508914
0000508915
0000508914
0000508915
0000485077

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Mary M Torregrossa et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 30(31), 10526-10533 (2010-08-06)
Extinction therapy has been proposed as a method to reduce the motivational impact of drug-associated cues to prevent relapse. Cue extinction therapy, however, takes place in a novel context (e.g., treatment facility), and is unlikely to be effective due to
M.K. Jain
Handbook of Enzyme Inhibitors, 112-112 (1982)
Simon P Byrne et al.
Depression and anxiety, 32(6), 408-414 (2015-03-17)
For exposure therapy to be successful, it is essential that fear extinction learning extends beyond the treatment setting. D-cycloserine (DCS) may facilitate treatment gains by increasing generalization of extinction learning, however, its effects have not been tested in children. We
Stefan G Hofmann et al.
Current psychiatry reports, 17(1), 532-532 (2014-11-22)
Although cognitive behavioral therapy (CBT) is a generally effective treatment for treating anxiety disorders, there is clearly still room for further improvements. Recent advances in neuroscience of extinction learning led to novel clinical strategies to augment exposure-based treatments with d-cycloserine
Michael L Sulkowski et al.
Current psychiatry reviews, 10(4), 317-324 (2014-11-11)
Variants of exposure therapy are effective for treating obsessive-compulsive and related disorders (OCRDs). However, significant numbers of patients do not respond adequately to exposure therapy resulting in continued distress and functional impairment. Therefore, novel approaches to augmenting exposure therapy are
View All Related Papers

Related Content

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service